Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM
Aim. To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM). Material and Methods. A total of 61 adults with type 1 DM were randomly and...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2015/807891 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558174779998208 |
|---|---|
| author | Metin Guclu Ozen Oz Gul Soner Cander Oguzkaan Unal Guven Ozkaya Emre Sarandol Canan Ersoy |
| author_facet | Metin Guclu Ozen Oz Gul Soner Cander Oguzkaan Unal Guven Ozkaya Emre Sarandol Canan Ersoy |
| author_sort | Metin Guclu |
| collection | DOAJ |
| description | Aim. To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM). Material and Methods. A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4 mg/day (n=30) or insulin alone (n=31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications. Results. Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels. While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 ± 3.06 to 4.99 ± 2.64, P=0.006; leptin 25.8 ± 17.6 to 20.1 ± 12.55, P=0.006; group 2: resistin 7.16 ± 2.30 to 5.57±2.48, P=0.031; leptin 16.72 ± 16.1 to 14.0 ± 13.4, P=0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 ± 1.98 to 13.16 ± 1.98, P=0.015, and fibrinogen 4.00 ± 1.08 to 3.46 ± 0.90, P=0.002). Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower. Discussion. The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM. These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion. |
| format | Article |
| id | doaj-art-59ef0eb3929c489eb68c39fb77632c2f |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-59ef0eb3929c489eb68c39fb77632c2f2025-02-03T01:33:03ZengWileyJournal of Diabetes Research2314-67452314-67532015-01-01201510.1155/2015/807891807891Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DMMetin Guclu0Ozen Oz Gul1Soner Cander2Oguzkaan Unal3Guven Ozkaya4Emre Sarandol5Canan Ersoy6Division of Endocrinology, Sevket Yılmaz Research and Education Hospital, 16310 Bursa, TurkeyDepartment of Endocrinology and Metabolism, School of Medicine, Uludağ University, 16210 Bursa, TurkeyDivision of Endocrinology, Sevket Yılmaz Research and Education Hospital, 16310 Bursa, TurkeyDepartment of Endocrinology and Metabolism, School of Medicine, Uludağ University, 16210 Bursa, TurkeyDepartment of Biostatistics, School of Medicine, Uludağ University, 16210 Bursa, TurkeyDepartment of Biochemistry, School of Medicine, Uludağ University, 16210 Bursa, TurkeyDepartment of Endocrinology and Metabolism, School of Medicine, Uludağ University, 16210 Bursa, TurkeyAim. To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM). Material and Methods. A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4 mg/day (n=30) or insulin alone (n=31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications. Results. Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels. While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 ± 3.06 to 4.99 ± 2.64, P=0.006; leptin 25.8 ± 17.6 to 20.1 ± 12.55, P=0.006; group 2: resistin 7.16 ± 2.30 to 5.57±2.48, P=0.031; leptin 16.72 ± 16.1 to 14.0 ± 13.4, P=0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 ± 1.98 to 13.16 ± 1.98, P=0.015, and fibrinogen 4.00 ± 1.08 to 3.46 ± 0.90, P=0.002). Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower. Discussion. The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM. These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion.http://dx.doi.org/10.1155/2015/807891 |
| spellingShingle | Metin Guclu Ozen Oz Gul Soner Cander Oguzkaan Unal Guven Ozkaya Emre Sarandol Canan Ersoy Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM Journal of Diabetes Research |
| title | Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM |
| title_full | Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM |
| title_fullStr | Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM |
| title_full_unstemmed | Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM |
| title_short | Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM |
| title_sort | effect of rosiglitazone and insulin combination therapy on inflammation parameters and adipocytokine levels in patients with type 1 dm |
| url | http://dx.doi.org/10.1155/2015/807891 |
| work_keys_str_mv | AT metinguclu effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm AT ozenozgul effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm AT sonercander effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm AT oguzkaanunal effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm AT guvenozkaya effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm AT emresarandol effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm AT cananersoy effectofrosiglitazoneandinsulincombinationtherapyoninflammationparametersandadipocytokinelevelsinpatientswithtype1dm |